Jun 08, 2021 / 02:30PM GMT
Terence C. Flynn - Goldman Sachs Group, Inc., Research Division - MD
Good morning, everybody. Thanks for joining us. I'm Terence Flynn, the U.S. biopharma analyst at Goldman Sachs. We're very pleased to have Regeneron this morning. From the company, we have Israel Lowy, who is Senior Vice President, Translational and Clinical Sciences, Oncology; and Andres Sirulnik, who is Senior Vice President, Translational and Clinical Sciences, Hematology.
Before we get started, I'm going to turn it over to Justin Holko from the IR team, and then we'll dive into Q&A.
Justin Holko - Regeneron Pharmaceuticals, Inc. - VP of IR
Thank you, Terence. Before we begin, I'd like to remind you that remarks made on today's event will include forward-looking statements about Regeneron. Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in the statement. A more complete description of these and other material risks can be found in Regeneron's SEC filings. We do not undertake
Regeneron Pharmaceuticals Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 08, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers